metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Cell therapy in amyotrophic lateral sclerosis: science and controversy
Journal Information
Vol. 25. Issue 8.
Pages 467-469 (January 2010)
Share
Share
Download PDF
More article options
Vol. 25. Issue 8.
Pages 467-469 (January 2010)
Full text access
Cell therapy in amyotrophic lateral sclerosis: science and controversy
Terapia celular en la esclerosis lateral amiotrófica: ciencia y controversia
Visits
1449
L. Galána,
Corresponding author
elainvestigacion@luciagalan.es

Corresponding author.
, A. Guerrero-Solaa, U. Gómez-Pinedob, J. Matias-Guiuc
a Unidad de ELA, Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
b Centro de Investigación Príncipe Felipe y CIBERNED, Valencia, Spain
c Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

Stem cell therapy is seen as a possible alternative for the treatment of different degenerative diseases, among which includes amyotrophic lateral sclerosis (ALS). Despite there being basic research works with this therapy in ALS, the mechanism of action of the implanted cells are still unclear. It is also unclear which type of cells to use (bone marrow, fat, dental pulp, etc.), or the most ideal administration route. Furthermore, clinical trials with mesenchymal stem cells are not very conclusive, therefore it has not been convincingly established as an alternative therapy in ALS or any other neurodegenerative disease. Despite the scientific evidence, several clinical trials have been conducted in the last few years that offer stem cell treatments for neurodegenerative diseases, giving rise to what is known as “cellular tourism”. This phenomenon has set off alarms and reactions in the scientific community. The application of these therapies must be performed following the good clinical practice guidelines in research, evidence based methodology and international ethical and scientific recommendations.

Keywords:
Amyotrophic lateral sclerosis
Stem cells
Neurodegenerative disease
Cell therapy
Resumen

La terapia con células madre se vislumbra como una posible terapia alternativa al tratamiento de diferentes patologías degenerativas, entre las cuales se encuentra la esclerosis lateral amiotrófica (ELA). En la actualidad, a pesar de que existen trabajos de investigación básica con esta terapia en la ELA, todavía quedan sin esclarecer los mecanismos de actuación de las células madre implantadas, además de no tener claro el tipo de células a utilizar (médula ósea, grasa, pulpa dentaria, etc.) y vía de administración más idónea. A su vez, existen ensayos clínicos con células madre mesenquimales con resultados poco concluyentes, por lo que no se ha podido establecer con contundencia como una terapia alternativa en ELA o cualquier otra enfermedad neurodegenerativa. A pesar de las evidencias científicas, en los últimos años han aparecido diferentes clínicas que ofrecen tratamientos con células madre para enfermedades neurodegenerativas, dando lugar a lo que se conoce como “turismo celular”. Este fenómeno ha activado alarmas y reacciones en la comunidad científica. La aplicación de estas terapias se debe realizar siguiendo las normas de buena práctica clínica en investigación, la metodología basada en la evidencia y las recomendaciones éticas y científicas internacionales

Palabras clave:
Esclerosis lateral amiotrófica
Células madre
Enfermedad neurodegenerativa
Terapia celular
Full text is only aviable in PDF
References
[1.]
G. Bensimon, L. Lacomblez, V. Meininger, ALS/Riluzole Study Group.
A controlled trial of riluzole in amyotrophic lateral sclerosis.
N Engl J Med, 330 (1994), pp. 585-591
[2.]
O. Lindvall, Z. Kokaia.
Stem cells in human neurodegenerative disorders—time for clinical translation?.
J Clin Invest, 120 (2010), pp. 29-40
[3.]
J. Matias-Guiu, J.A. Barcia, J.M. García-Verdugo, L. Galán, A. Vela, R. García-Ramos.
Terapia celular en la Esclerosis Lateral Amiotrófica.
Neurologia, 23 (2008), pp. 226-237
[4.]
S.T. Papadeas, N.J. Maragakis.
Advances in stem cell research for amyotrophic lateral sclerosis.
Curr Opin Biotechnol, 20 (2009), pp. 545-551
[5.]
N. Amariglio, A. Hirshberg, B.W. Scheithauer, Y. Cohen, R. Loewenthal, L. Trakhtenbrot, et al.
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.
PLoS Med, 6 (2009), pp. e1000029
[6.]
S.H. Appel, J.I. Engelhardt, J.S. Henkel, L. Siklos, D.R. Beers, A.A. Yen, et al.
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis.
[7.]
H.R. Martínez, M.T. González-Garza, J.E. Moreno-Cuevas, E. Caro, E. Gutiérrez-Jiménez, J.J. Segura.
Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.
Cytotherapy, 11 (2009), pp. 26-34
[8.]
L. Mazzini, K. Mareschi, I. Ferrero, E. Vassallo, G. Oliveri, N. Nasuelli, et al.
Stem cell treatment in amyotrophic lateral sclerosis.
J Neurol Sci, 265 (2008), pp. 78-83
[9.]
H. Deda, M.C. Inci, A.E. Kurekci, A. Sav, K. Kayihan, E. Ozgun, et al.
Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.
Cytotherapy, 11 (2009), pp. 18-25
[10.]
J.D. Mitchell, G.D. Borasio.
Amyotrophic lateral sclerosis.
Lancet, 369 (2007), pp. 2031-2041
[11.]
S. Boillee, C. Vande Velde, D.W. Cleveland.
ALS: a disease of motor neurons and their nonneuronal neighbors.
[12.]
J.M. Ravits, A.R. La Spada.
ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration.
Neurology, 73 (2009), pp. 805-811
[13.]
J. Gao, R.E. Coggeshall, Y.I. Tarasenko, P. Wu.
Human neural stem cell-derived cholinergic neurons innervate muscle in motoneuron deficient adult rats.
Neuroscience, 131 (2005), pp. 257-262
[14.]
H. Wichterle, I. Lieberam, J.A. Porter, T.M. Jessell.
Directed differentiation of embryonic stem cells into motor neurons.
Cell, 110 (2002), pp. 385-397
[15.]
A.C. Lepore, B. Rauck, C. Dejea, A.C. Pardo, M.S. Rao, J.D. Rothstein, et al.
Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease.
Nat Neurosci, 11 (2008), pp. 1294-1301
[16.]
M. Suzuki, J. McHugh, C. Tork, B. Shelley, S.M. Klein, P. Aebischer, et al.
GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS.
[17.]
M. Suzuki, J. McHugh, C. Tork, B. Shelley, A. Hayes, I. Bellantuono, et al.
Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS.
Mol Ther, 16 (2008), pp. 2002-2010
[18.]
A. Vercelli, O.M. Mereuta, D. Garbossa, G. Muraca, K. Mareschi, D. Rustichelli, et al.
Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinfl ammation in mouse model of amyotrophic lateral sclerosis.
Neurobiol Dis, 31 (2008), pp. 395-405
[19.]
S. Garbuzova-Davis, C.D. Sanberg, N. Kuzmin-Nichols, A.E. Willing, C. Gemma, P.C. Bickford, et al.
Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose.
[20.]
D.R. Beers, J.S. Henkel, W. Zhao, J. Wang, S.H. Appel.
CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS.
Proc Natl Acad Sci U S A, 105 (2008), pp. 15558-15563
[21.]
I. Badayan, M.E. Cudkowicz.
Is it too soon for mesenchymal stem cell trials in people with ALS?.
Amyotroph Lateral Scler, 9 (2008), pp. 321-322
[22.]
D. Lau, U. Ogbogu, B. Taylor, T. Stafinski, D. Menon, T. Caulfield.
Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine.
Cell Stem Cell, 3 (2008), pp. 591-594
[23.]
I. Hyun, O. Lindvall, L. Ahrlund-Richter, E. Cattaneo, M. Cavazzana- Calvo, G. Cossu, et al.
New ISSCR guidelines underscore major principles for responsible translational stem cell research.
Cell Stem Cell, 3 (2008), pp. 607-609
Copyright © 2010. Sociedad Española de Neurología
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.nrleng.2021.07.004
No mostrar más